Researchers at the University of California, Davis have developed adjuvants that promotes the efficacy of HIV vaccines.
Vaccines and antiretroviral therapy (ART) have enhanced the life expectancy and quality of life worldwide for many patients carrying the human immunodeficiency virus (HIV). However, some patients respond poorly to current treatment protocols, and ART options are limited in many parts of the world. Thus, additional prevention and treatment alternatives remain a healthcare system priority globally.
Researchers at the University of California, Davis have developed a method of improving a host's immune response to a HIV vaccine by combining the vaccine with an adjuvant. These adjuvants can include interferon-induced proteins and - in some cases - be administered transdermally. In addition, the vaccine itself can be modified to optimize the effective interactions between the vaccine components and the adjuvant. Combining adjuvants with a vaccine creates a stronger patient immune system; as the body's response activates immune cells that help mitigate off-target effects. Increased immunity also enhances the immune response of the host's HIV-relevant organs.